Sort
15,842 grants matching “pancreatic cancer”
TUMOR PROMOTING EFFECTS OF TGF-BETA1
$39,232Vanderbilt University · F32 · FY2000 · DK
Roles of the Insulin-like Growth Factor Axis in Pre-Type 1 Diabetes Immune Regulation
$39,223Melanie R Shapiro · University Of Florida · F31 · FY2018 · DK
The Novel Role of REST in the Development of Pancreatic Ductal Adenocarcinoma
$39,223Julie Bray · University Of Florida · F31 · FY2018 · CA
Role of Gastrokine 2 in pancreatic cancer development
$39,211Whitney Jean Bell · Univ Of North Carolina Chapel Hill · F31 · FY2023 · CA
Engineered tolerogenic exosomes for treating type 1 diabetes autoimmunity
$39,188Matthew Becker · University Of Florida · F31 · FY2020 · DK
The Role of SHIP-1 in the Modulation of Immunoregulatory Cells in Pancreatic Canc
$39,188Tomar Ghansah · University Of South Florida · R21 · FY2014 · CA
Assessing the Transcriptional and Signaling Basis of Heterogeneity in the Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma
$39,135Michelle C Barbeau · University Of Virginia · F31 · FY2023 · CA
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
$39,055Dillon Matthew Voss · State University New York Stony Brook · F30 · FY2022 · CA
Characterizing the biochemistry and dynamics of the immune suppressive CXCL12 coat in pancreatic cancer
$39,028Philip Andrew Moresco · State University New York Stony Brook · F30 · FY2022 · CA
Metabolism of Extracellular Matrix Supports Pancreatic Cancer Growth
$39,007Peter Kim · University Of Michigan At Ann Arbor · F31 · FY2021 · CA
PDAC Antibody Core
$38,987James A Decaprio · Dana-Farber Cancer Inst · P01 · FY2009 · CA
Pre-Clinical Evaluation of Novel Therapeutics for PDA
$38,976Kenneth P Olive · Cambridge Research Institute (Cruk) · F32 · FY2006 · CA
Tumor Biology Research Program
$38,872Wael El-Rifai · University Of Miami School Of Medicine · P30 · FY2021 · CA
Synthesis, and Evaluation of Potent and Selective MEK4 Inhibitors as a Targeted Therapeutic for Metastatic Pancreatic Ductal Adenocarcinoma
$38,801Ada Jade Kwong · Northwestern University · F31 · FY2020 · CA
Tumor Biology Research Program
$38,794Sandra W Ryeom · University Of Pennsylvania · P30 · FY2019 · CA
Mechanisms of cancer dormancy and drug resistance
$38,788Aparna C Ranganathan · State University Of New York At Albany · F32 · FY2007 · CA
GENETIC MECHANISMS IN EXPERIMENTAL PANCREATIC CANCER
$38,762University Of Wisconsin Madison · R01 · FY2001 · CA
Tumor Biology Research Program
$38,760Sandra W Ryeom · University Of Pennsylvania · P30 · FY2020 · CA
Design and Development of a Small Molecule-controlled Activator of RAS
$38,752John Christopher Rose · University Of Washington · F30 · FY2015 · CA
The Novel Role of REST in the Development of Pancreatic Ductal Adenocarcinoma
$38,743Julie Bray · University Of Florida · F31 · FY2017 · CA
Development of Targeted Nanotechnology Platform for Pancreatic Cancer
$38,684Subhash C. Chauhan · University Of Tennessee Health Sci Ctr · R01 · FY2019 · CA
Tumor-Specific Nanocontrast Agents for Improved Detection of Pancreatic Cancer
$38,634William Maccuaig · University Of Oklahoma · F31 · FY2023 · CA
Screening for antagonists of nuclear receptor LRH-1 in pancreatic cancer cells
$38,625Robert J Fletterick · University Of California, San Francisco · R03 · FY2012 · MH
Cancer Epidemiology and Prevention Program
$38,529James G. Herman · University Of Pittsburgh At Pittsburgh · P30 · FY2025 · CA
Characterization of the PKM2-RAS Interaction as a Novel Metabolic Vulnerability of RAS-driven Tumors
$38,523Juan Andres Kochen Rossi · New York University School Of Medicine · F31 · FY2022 · CA